UNASSIGNED: The Surveillance, Epidemiology and End Results (SEER) database was used to determine the treatment patterns, outcomes and cost of therapy in elderly @entity1 with @entity463 ( @entity463 ). The SEER-Medicare linked database was used to identify @entity1 aged >66 years with @entity463 diagnosed between 1997 and 2009. The @entity1 were stratified by initial treatment following diagnostic surgery (resection or biopsy) into 6 groups as follows: No treatment, standard radiation therapy (SRT) with and without concurrent @entity2903 ( @entity2904 ), hypofractionated @entity138 (HRT) with and without concurrent @entity2904 , or @entity2904 alone. The 3,759 @entity1 identified had a median age of 74 years (range, 66-97 years). A total of ~48% of the @entity1 received SRT without @entity2904 ; ~10% received SRT with concurrent @entity2904 ; ~29% received no treatment; ~10% received HRT without @entity2904 ; ~1% received HRT with @entity2904 ; and <1% received @entity2904 alone. Untreated @entity1 had a median survival of 2 months (range, 0-89 months). @entity1 treated with SRT with and without concurrent @entity2904 had a median survival of 11 and 9 months, respectively (P=0.01). @entity1 treated with HRT with and without @entity2904 or @entity2904 alone had a median survivals of 3 months [adjusted hazard ratio (AHR)=0.48; 95% confidence interval (CI): 0.36-0.66], 4 months (AHR=0.55; 95% CI: 0.49-0.62) and 6 months (AHR=0.43; 95% CI: 0.29-0.62), respectively. The median post-surgery total treatment cost for @entity1 receiving HRT with and without @entity2904 or @entity2904 alone was 63,915, 42,834 and 48,298 USD, respectively. Standard @entity138 with concurrent @entity2904 was associated with improved survival, even in @entity1 aged >75 years. HRT with and without concurrent @entity2904 and @entity2904 alone improved survival compared to the no treatment group. Therefore, in certain cases, HRT or @entity2904 alone may be more cost-effective, with similar survival outcomes. The various treatment options highlight the need for geriatric assessment tools to aid in therapeutic decision making.

A Surveillance, Epidemiology and End Results-Medicare data analysis of elderly @entity1 with XXXX : Treatment patterns, outcomes and cost.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity138 :: ('MESH:C563738', 'Disease') :: ['RT'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity2904 :: ('CHEBI:72564', 'Chemical') :: ['TMZ'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma multiforme', 'GBM']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma multiforme']
